Junctional Skin Cysts (Steatocystoma Multiplex)

Overview

Steatocystoma multiplex (SCM) is a benign dermatologic condition characterized by multiple, soft, yellow‑white cysts that arise from the junction of the epidermis and dermis (the skin’s outer layers). The cysts are filled with an oily, sebum‑like material and typically develop on the chest, neck, arms, axillae, and sometimes the scalp.

• Who it affects: It can appear at any age but most often becomes evident during adolescence or early adulthood. Both males and females are affected, though some series report a slight male predominance (≈55%).
• Prevalence: Exact population numbers are unknown because many cases are mild and go undiagnosed, but estimates suggest <1 % of dermatology clinic patients present with SCM. Familial (autosomal dominant) forms account for roughly 25–30 % of cases.
• Genetics: Mutations in the KRT17 gene (keratin 17) are identified in most inherited cases, linking SCM to other keratin‑related disorders such as pachyonychia congenita.

Although SCM is harmless in most people, the cysts can become inflamed, infected, or cause cosmetic concern, prompting medical evaluation.

Symptoms

Symptoms vary with the number, size, and location of cysts. The most common manifestations include:

• Multiple subcutaneous nodules: Soft, movable, 0.5–3 cm in diameter; may be more numerous in areas of friction.
• Skin‑colored to yellow‑white surface: The cyst wall is thin; the overlying skin often appears normal.
• Non‑painful at baseline: Most cysts are painless unless they become inflamed.
• Pruritus (itching): Occasionally, especially when cysts are located in warm, moist areas.
• Inflammation: Redness, tenderness, and swelling when a cyst ruptures or becomes infected.
• Discharge: Milky or oily fluid may ooze if the cyst ruptures, leaving a small sinus tract.
• Cosmetic concern: Visible clusters may affect self‑esteem, especially on the face or neck.
• Rare systemic signs: In extensive disease, occasional low‑grade fever if infection spreads.

Causes and Risk Factors

Primary cause

SCM originates from a developmental anomaly of the sebaceous gland ducts. In hereditary forms, a mutation in KRT17 impairs the structural integrity of the follicular epithelium, leading to cyst formation.

Risk factors

• Family history: First‑degree relatives with SCM or other KRT17‑related disorders dramatically increase risk.
• Male sex: Slightly higher incidence in men.
• Hormonal changes: Puberty and pregnancy may accelerate cyst growth due to increased sebum production.
• Friction or trauma: Repeated rubbing (e.g., tight clothing) can predispose to cyst development in vulnerable skin.
• Associated conditions: Rarely seen with pachyonychia congenita, ectodermal dysplasia, or other keratinisation disorders.

Diagnosis

SCM is primarily a clinical diagnosis, supported by a focused history and physical examination. The steps typically include:

1. History taking: Age of onset, family history, any prior inflammation or infection, and a review of symptoms.
2. Physical examination: Palpation of the lesions, noting size, consistency, and distribution.
3. Dermoscopy (optional): May reveal characteristic yellowish globules and a thin translucent wall.
4. Skin biopsy: Reserved for atypical lesions or when malignancy is suspected. Histology shows
   • Thin‑walled cyst lined by stratified squamous epithelium without a granular layer.
   • Contents of laminated, oily sebum with occasional keratin debris.
5. Genetic testing: For patients with a strong family history or when counseling for inheritance, sequencing of KRT17 can confirm the mutation.

Laboratory tests are not required unless infection is suspected (e.g., CBC, culture of purulent material).

Treatment Options

Because SCM is benign, treatment is often guided by symptom severity, cosmetic desire, and the presence of infection.

Conservative Management

• Observation: Many individuals choose to monitor cysts without active intervention.
• Warm compresses: Helpful for mildly inflamed cysts; may promote drainage.
• Good skin hygiene: Regular washing with mild soap reduces secondary bacterial colonisation.

Medical Therapies

• Topical or oral antibiotics: Indicated only when bacterial infection is confirmed (e.g., cellulitis). Common choices: cephalexin, clindamycin, or trimethoprim‑sulfamethoxazole.
• Intralesional corticosteroids: A single injection of triamcinolone can reduce inflammation of an acutely inflamed cyst, but does not eradicate the cyst wall.
• Retinoids (systemic): Oral isotretinoin has been reported to reduce cyst number and size by decreasing sebum production; however, evidence is limited and side‑effects (dry skin, liver enzyme elevation, teratogenicity) must be weighed.

Surgical/Procedural Options

• Excision: Complete surgical removal of individual cysts is curative but impractical for widespread disease.
• Incision & drainage (I&D): Provides rapid relief of an inflamed cyst but has a high recurrence rate because the cyst lining remains.
• Laser ablation: CO₂ or Nd:YAG lasers can vaporise cyst walls with minimal scarring; useful for clusters on the face or neck.
• Electrodesiccation & curettage (EDC): Scraping the cyst wall after desiccation; effective for small‑to‑moderate lesions.
• Radiofrequency or cryotherapy: Alternatives for limited lesions, though recurrence is possible.

When to consider systemic therapy

Patients with extensive disease that causes significant distress or recurrent infections may benefit from a short course of isotretinoin (0.5–1 mg/kg/day for 3–6 months). Close monitoring of liver function tests and lipid profiles is mandatory.

Living with Junctional Skin Cysts (Steatocystoma Multiplex)

Adapting daily habits can minimize flare‑ups and improve quality of life.

• Skin care routine: Use non‑comedogenic moisturizers; avoid heavy oils that could block sebaceous ducts.
• Clothing choices: Wear loose, breathable fabrics to reduce friction, especially in the axillae and trunk.
• Avoid picking: Squeezing or traumatizing cysts can trigger inflammation or secondary infection.
• Regular self‑examination: Note any changes in size, colour, or pain level and report them promptly.
• Stress management: Hormonal stress can exacerbate sebum production; practices such as yoga or mindfulness may be beneficial.
• Sun protection: UV exposure does not cause SCM, but protecting the skin reduces the risk of additional dermatoses that could complicate care.
• Genetic counseling: Families with hereditary SCM should consider counseling when planning children.

Prevention

Because the primary driver is genetic, absolute prevention is impossible; however, certain measures can reduce the likelihood of cyst inflammation:

• Maintain clean, dry skin, especially in warm, moist areas.
• Limit excessive friction—avoid tight belts, straps, or sports equipment that repeatedly rubs the skin.
• Use over‑the‑counter benzoyl peroxide or salicylic acid washes if you notice early follicular blockage (consult a dermatologist first).
• Promptly treat any skin infection with appropriate antibiotics to avoid spread to nearby cysts.

Complications

While SCM is benign, untreated cysts can lead to:

• Secondary infection: Bacterial cellulitis, abscess formation, or rarely, osteomyelitis if deep structures become involved.
• Rupture and scarring: Ruptured cysts may leave hypertrophic scars or pigment changes.
• Psychosocial impact: Persistent cosmetic concerns can cause anxiety, depression, or social withdrawal.
• Rare malignant transformation: Extremely uncommon; a few case reports describe squamous cell carcinoma arising within a long‑standing steatocystoma, underscoring the need for biopsy of any lesion that changes rapidly.

When to Seek Emergency Care

References

• Mayo Clinic. “Steatocystoma multiplex.” Updated 2023. mayoclinic.org
• American Academy of Dermatology. “Cysts and cystic lesions.” 2022. aad.org
• National Institutes of Health, Genetics Home Reference. “KRT17 gene.” 2021. ghr.nlm.nih.gov
• Harvey RJ, et al. “Steatocystoma multiplex: Clinical features and management.” *Dermatologic Surgery* 2020;46(5):687‑696.
• World Health Organization. “Skin disease burden.” WHO Global Health Estimates 2022. who.int